Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group

References

• Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420–3427.
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–295.
   PubMed Web of Science ®Google Scholar
• Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541–4549.
   PubMed Web of Science ®Google Scholar
• Mahmood S, Bridoux F, Venner CP, et al. Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study. Lancet Haematol. 2015;2(6):e241-250–e250.
   Web of Science ®Google Scholar
• Palladini G, Schonland SO, Sanchorawala V, et al. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid. 2021;28(1):1–2.
   PubMed Web of Science ®Google Scholar
• Manwani R, Cohen O, Sharpley F, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134(25):2271–2280.
   PubMed Web of Science ®Google Scholar
• Sidana S, Dispenzieri A, Murray DL, et al. Revisiting complete response in light chain amyloidosis. Leukemia. 2020;34(5):1472–1475.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Gertz MA, Lacy MQ, et al. Refining amyloid complete hematological response: quantitative serum free light chains superior to ratio. Am J Hematol. 2020;95(11):1280–1287.
   PubMed Web of Science ®Google Scholar
• Milani P, Basset M, Nuvolone M, et al. Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy. Blood Cancer J. 2020;10(8):90.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Fotiou D, Theodorakakou F, et al. Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. Amyloid. 2021;28(1):3–11.
   PubMed Web of Science ®Google Scholar
• Ravichandran S, Mahmood S, Wisniowski B, et al. A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosis. Br J Haematol. 2022. doi: 10.1111/bjh.18216
   PubMed Web of Science ®Google Scholar
• Palladini G, Paiva B, Wechalekar A, et al. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. Blood Cancer J. 2021;11(2):34.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Kostopoulos IV, Theodorakakou F, et al. Next generation flow cytometry for MRD detection in patients with AL amyloidosis. Amyloid. 2021;28(1):19–23.
   PubMed Web of Science ®Google Scholar
• Cibeira MT, Ortiz-Perez JT, Quintana LF, et al. Supportive care in AL amyloidosis. Acta Haematol. 2020;143(4):335–342.
   PubMed Web of Science ®Google Scholar
• Cuddy SAM, Dorbala S, Falk RH. Complexities and pitfalls in cardiac amyloidosis. Circulation. 2020;142(4):409–415.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Boccadoro M, Gertz M, et al. Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid. 2022;29(1):1–7.
   PubMed Web of Science ®Google Scholar
• Palladini G, Milani P, Foli A, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica. 2014;99(4):743–750.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol. 2020;38(28):3252–3260.
   PubMed Web of Science ®Google Scholar
• Oliva L, Orfanelli U, Resnati M, et al. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. Blood. 2017;129(15):2132–2142.
   PubMed Web of Science ®Google Scholar
• Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011;118(4):865–873.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Anagnostopoulos A, Roussou MT, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica. 2007;92(10):1351–1358.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28(6):1031–1037.
   PubMed Web of Science ®Google Scholar
• Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612–615.
   PubMed Web of Science ®Google Scholar
• Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391–4394.
   PubMed Web of Science ®Google Scholar
• Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387–4390.
   PubMed Web of Science ®Google Scholar
• Venner CP, Gillmore JD, Sachchithanantham S, et al. A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia. 2014;28(12):2304–2310.
   PubMed Web of Science ®Google Scholar
• Jaccard A, Comenzo RL, Hari P, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (mayo clinic stage III). Haematologica. 2014;99(9):1479–1485.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Dispenzieri A, Kumar SK, et al. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia. 2017;31(7):1562–1569.
   PubMed Web of Science ®Google Scholar
• Bochtler T, Hegenbart U, Kunz C, et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015;33(12):1371–1378.
   PubMed Web of Science ®Google Scholar
• Cole DC, Frishman WH. Cardiovascular complications of proteasome inhibitors used in multiple myeloma. Cardiol Rev. 2018;26(3):122–129.
   PubMed Web of Science ®Google Scholar
• Bruce JT, Tran JM, Phillips G, et al. Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012;12(5):325–329.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kastritis E, Wechalekar AD, et al. A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. Leukemia. 2022;36(1):225–235.
   PubMed Web of Science ®Google Scholar
• Sanchez L, Landau HJ, Rosenbaum CA, et al. A phase 1/2 study to assess safety and dose of ixazomib in combination with cyclophosphamide and dexamethasone in newly diagnosed patients with light chain (AL) amyloidosis. Blood. 2019;134(Supplement_1):3128–3128.
   Google Scholar
• Muchtar E, Gertz MA, Laplant B, et al. Phase 2 trial of ixazomib, cyclophosphamide and dexamethasone for treatment of previously untreated light chain amyloidosis. Blood. 2020;136(Supplement 1):52–53.
   Google Scholar
• Wei Z, Zhang Y, Li J, et al. Upfront ixazomib plus dexamethasone induce promptly hematological response in patients with light-chain amyloidosis. Blood. 2019;134(Supplement_1):1908–1908.
   Google Scholar
• Manwani R, Mahmood S, Sachchithanantham S, et al. Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. Br J Haematol. 2019;187(5):638–641.
   PubMed Web of Science ®Google Scholar
• Garg M, Hall A, Jenner M, et al. A phase 1 study of carfilzomib-thalidomide-dexamethasone in patients with relapsed/refractory AL amyloidosis – catalyst trial results. Blood. 2019;134(Supplement_1):1890–1890.
   Google Scholar
• Dispenzieri A, Lacy MQ, Rajkumar SV, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid. 2003;10(4):257–261.
   PubMed Web of Science ®Google Scholar
• Cibeira MT, Oriol A, Lahuerta JJ, et al. Phase II trial of lenalidomide, dexamethasone and cyclophosphamide (lendexal) for previously untreated patients with light-chain amyloidosis. Haematologica. 2014;99:117–118.
   Web of Science ®Google Scholar
• Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed light-chain (AL)-amyloidosis: a multicentre phase I/II dose escalation study. Amyloid. 2010;17:87–88.
   Web of Science ®Google Scholar
• Kastritis E, Dialoupi I, Gavriatopoulou M, et al. Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. Blood Adv. 2019;3(20):3002–3009.
   PubMed Web of Science ®Google Scholar
• Milani P, Sharpley F, Schonland SO, et al. Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients. Amyloid. 2020;27(4):231–236.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Buadi F, Laumann K, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012;119(23):5397–5404.
   PubMed Web of Science ®Google Scholar
• Zonder JA, Sanchorawala V, Kukreti V, et al. Phase I trial of pomalidomide, bortezomib, and dexamethasone as frontline treatment of AL amyloidosis. Blood. 2019;134(Supplement 1):1845.
   Google Scholar
• Kaufman GP, Schrier SL, Lafayette RA, et al. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017;130(7):900–902.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Sarosiek S, Schulman A, et al. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. Blood. 2020;135(18):1541–1547.
   PubMed Web of Science ®Google Scholar
• Roussel M, Merlini G, Chevret S, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. Blood. 2020;135(18):1531–1540.
   PubMed Web of Science ®Google Scholar
• Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136(1):71–80.
   PubMed Web of Science ®Google Scholar
• Comenzo R, Palladini G, Kastritis E, et al. Subcutaneous daratumumab with bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed light chain (AL) amyloidosis: 18-month analysis of the phase 3 ANDROMEDA study. Blood. 2021;138(Supplement 1):159–159.
   Google Scholar
• Kastritis E, Roussakis P, Kostopoulos IV, et al. Short daratumumab consolidation in patients with AL amyloidosis or LCDD improves complete response rates and modifies bone marrow microenvironment. Blood. 2020;136(Supplement 1):25–25.
   Google Scholar
• Le Bras F, Molinier-Frenkel V, Guellich A, et al. Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis. Eur J Cancer. 2017;76:183–187.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Minnema MC, Dimopoulos MA, et al. Efficacy and safety of daratumumab monotherapy in newly diagnosed patients with stage 3b light chain amyloidosis: a phase 2 study by the European myeloma network. Blood. 2021;138(Supplement 1):2730–2730.
   Google Scholar
• Kimmich CR, Terzer T, Benner A, et al. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. Blood. 2020;135(18):1517–1530.
   PubMed Web of Science ®Google Scholar
• Luo MM, Zhu PP, Nnane I, et al. Population pharmacokinetics and exposure-response modeling of daratumumab subcutaneous administration in patients with light-chain amyloidosis. J Clin Pharmacol. 2022;62(5):656–669.
   PubMed Web of Science ®Google Scholar
• Sidana S, Larson DP, Greipp PT, et al. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia. 2020;34(5):1373–1382.
   PubMed Web of Science ®Google Scholar
• Milani P, Schonland S, Merlini G, et al. Treatment of AL amyloidosis with bendamustine: a study of 122 patients. Blood. 2018;132(18):1988–1991.
   PubMed Web of Science ®Google Scholar
• Manwani R, Sachchithanantham S, Mahmood S, et al. Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine. Blood. 2018;132(7):761–764.
   PubMed Web of Science ®Google Scholar
• Buske C, Dimopoulos MA, Grunenberg A, et al. Bortezomib in combination with dexamethasone, rituximab and cyclophosphamide (B-DRC) as first – line treatment of waldenstrom's macroglobulinemia: results of a prospectively randomized multicenter European phase II trial. Blood. 2020;136(Supplement 1):26–26.
   Google Scholar
• Dimopoulos MA, Roussou M, Kastritis E, et al. Primary treatment of waldenstrom's macroglobulinemia with dexamethasone, rituximab and cyclophosphamide (DRC): final analysis of a phase II study. Blood. 2012;120(21):438–438.
   Web of Science ®Google Scholar
• Ghobrial IM, Hong FX, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed/refractory waldenstrom's macroglobulinemia. Blood. 2009;114(22):1067.
   Web of Science ®Google Scholar
• Pika T, Hegenbart U, Flodrova P, et al. First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival. Blood. 2018;131(3):368–371.
   PubMed Web of Science ®Google Scholar
• Sidiqi MH, Buadi FK, Dispenzieri A, et al. Autologous stem cell transplant for IgM-associated amyloid light-chain amyloidosis. Biol Blood Marrow Transplant. 2019;25(3):e108–e111.
   PubMedGoogle Scholar
• Tandon N, Sidana S, Rajkumar SV, et al. Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. Amyloid. 2017;24(3):183–188.
   PubMed Web of Science ®Google Scholar
• Palladini G, Milani P, Foli A, et al. Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. Blood. 2018;131(5):525–532.
   PubMed Web of Science ®Google Scholar
• Palladini G, Merlini G. When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression. Blood Adv. 2019;3(2):212–215.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V. Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details. Blood Adv. 2019;3(2):216–218.
   PubMed Web of Science ®Google Scholar
• Cohen OC, Sharpley F, Gillmore JD, et al. Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis. Br J Haematol. 2020;189(4):643–649.
   PubMed Web of Science ®Google Scholar
• Milani P, Fazio F, Basset M, et al. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate. Am J Hematol. 2020;95(8):900–905.
   PubMed Web of Science ®Google Scholar
• Cohen OC, Brodermann MH, Blakeney IJ, et al. Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis. Amyloid. 2020;27(3):200–205.
   PubMed Web of Science ®Google Scholar
• Antonioli E, Staderini M, Pilerci S, et al. Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience. Leuk Lymphoma. 2020;61(13):3255–3258.
   PubMed Web of Science ®Google Scholar
• Jelinek T, Kufova Z, Hajek R. Immunomodulatory drugs in AL amyloidosis. Crit Rev Oncol Hematol. 2016;99:249–260.
   PubMed Web of Science ®Google Scholar
• Basset M, Kimmich CR, Schreck N, et al. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up. Br J Haematol. 2021;195(2):230–243.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007;109(2):492–496.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Hayman SR, Buadi FK, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012;119(21):4860–4867.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Terpos E, Roussou M, et al. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood. 2012;119(23):5384–5390.
   PubMed Web of Science ®Google Scholar
• Palladini G, Milani P, Foli A, et al. A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. Blood. 2017;129(15):2120–2123.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Shelton AC, Lo S, et al. Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood. 2016;128(8):1059–1062.
   PubMed Web of Science ®Google Scholar
• Lentzsch S, Lagos GG, Comenzo RL, et al. Bendamustine with dexamethasone in relapsed/refractory systemic light-chain amyloidosis: results of a phase II study. J Clin Oncol. 2020;38(13):1455–1462.
   PubMed Web of Science ®Google Scholar
• Gupta VA, Ackley J, Kaufman JL, et al. BCL2 family inhibitors in the biology and treatment of multiple myeloma. Blood Lymphat Cancer. 2021;11:11–24.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1630–1642.
   PubMed Web of Science ®Google Scholar
• Premkumar VJ, Lentzsch S, Pan S, et al. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer J. 2021;11(1):10.
   PubMed Web of Science ®Google Scholar
• Maples KT, Johnson C, Lonial S. Antibody treatment in multiple myeloma. Clin Advanc Hematol Oncol. 2021;19(3):166–174.
   PubMed Web of Science ®Google Scholar
• Trudel S, Lendvai N, Popat R, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncl. 2018;19(12):1641–1653.
   PubMed Web of Science ®Google Scholar
• Rosenzweig M, Urak R, Walter M, et al. Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis. Cytotherapy. 2017;19(7):861–866.
   PubMed Web of Science ®Google Scholar
• Iqbal SM, Stecklein K, Sarow J, et al. Elotuzumab in combination with lenalidomide and dexamethasone for treatment-resistant immunoglobulin light chain amyloidosis with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2019;19(1):e33–e36.
   PubMed Web of Science ®Google Scholar
• Westermark P. Localized AL amyloidosis: a suicidal neoplasm? Ups J Med Sci. 2012;117(2):244–250.
   PubMed Web of Science ®Google Scholar
• Hamidi Asl K, Liepnieks JJ, Nakamura M, et al. Organ-specific (localized) synthesis of Ig light chain amyloid. J Immunol. 1999;162(9):5556–5560.
   PubMed Web of Science ®Google Scholar
• Stuhlmann-Laeisz C, Schönland SO, Hegenbart U, et al. AL amyloidosis with a localized B cell neoplasia. Virchows Arch. 2019;474(3):353–363.
   PubMed Web of Science ®Google Scholar
• Kourelis TV, Kyle RA, Dingli D, et al. Presentation and outcomes of localized immunoglobulin light chain amyloidosis: the mayo clinic experience. Mayo Clin Proc. 2017;92(6):908–917.
   PubMed Web of Science ®Google Scholar
• Basset M, Hummedah K, Kimmich C, et al. Localized immunoglobulin light chain amyloidosis: novel insights including prognostic factors for local progression. Am J Hematol. 2020;95(10):1158–1169.
   Web of Science ®Google Scholar
• Meijer JM, Schonland SO, Palladini G, et al. Sjogren's syndrome and localized nodular cutaneous amyloidosis: coincidence or a distinct clinical entity? Arthritis Rheum. 2008;58(7):1992–1999.
   PubMedGoogle Scholar
• Grogg KL, Aubry MC, Vrana JA, et al. Nodular pulmonary amyloidosis is characterized by localized immunoglobulin deposition and is frequently associated with an indolent B-cell lymphoproliferative disorder. Am J Surg Pathol. 2013;37(3):406–412.
   PubMed Web of Science ®Google Scholar
• Ryan RJ, Sloan JM, Collins AB, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with amyloid deposition: a clinicopathologic case series. Am J Clin Pathol. 2012;137(1):51–64.
   PubMed Web of Science ®Google Scholar
• Basset M, Defrancesco I, Milani P, et al. Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis. Blood. 2020;135(4):293–296.
   PubMed Web of Science ®Google Scholar
• Burns H, Phillips N. Laryngeal amyloidosis. Curr Opin Otolaryngol Head Neck Surg. 2019;27(6):467–474.
   PubMed Web of Science ®Google Scholar
• Truong MT, Kachnic LA, Grillone GA, et al. Long-term results of conformal radiotherapy for progressive airway amyloidosis. Int J Radiat Oncol Biol Phys. 2012;83(2):734–739.
   PubMed Web of Science ®Google Scholar
• Copperman TS, Truong MT, Berk JL, et al. External beam radiation for localized periocular amyloidosis: a case series. Orbit. 2019;38(3):210–216.
   PubMed Web of Science ®Google Scholar
• Harris G, Lachmann H, Hawkins P, et al. One hundred cases of localized laryngeal amyloidosis – evidence for future management. Laryngoscope. 2021;131(6):E1912–E1917.
   PubMed Web of Science ®Google Scholar
• Wechalekar A, Antoni G, Al Azzam W, et al. Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label phase 2 study and an adjunctive immuno-PET imaging study. BMC Cardiovasc Disord. 2022;22(1):49.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Cohen AD, Comenzo RL, et al. Results of the phase 3 VITAL study of NEOD001 (birtamimab) plus standard of care in patients with light chain (AL) amyloidosis suggest survival benefit for mayo stage IV patients. Blood. 2019;134(Supplement_1):3166–3166.
   Google Scholar
• Van Doren L, Lentzsch S. Nonchemotherapy treatment of immunoglobulin light chain amyloidosis. Acta Haematol. 2020;143(4):373–380.
   PubMed Web of Science ®Google Scholar
• Edwards CV, Rao N, Bhutani D, et al. Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood. 2021;138(25):2632–2641.
   PubMed Web of Science ®Google Scholar
• Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. Faseb J. 2006;20(2):234–239.
   PubMed Web of Science ®Google Scholar
• Faravelli G, Raimondi S, Marchese L, et al. C. elegans expressing D76N beta2-microglobulin: a model for in vivo screening of drug candidates targeting amyloidosis. Sci Rep. 2019;9(1):19960.
   PubMedGoogle Scholar
• Wechalekar AD, Whelan C. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis. Blood Cancer J. 2017;7(3):e546.
   PubMedGoogle Scholar
• D'Souza A, Flynn K, Chhabra S, et al. Rationale and design of DUAL study: doxycycline to upgrade response in light chain (AL) amyloidosis (DUAL): a phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. Contemp Clin Trials Commun. 2017;8:33–38.
   PubMed Web of Science ®Google Scholar
• Shen KN, Fu WJ, Wu Y, et al. Doxycycline combined with bortezomib-cyclophosphamide-dexamethasone chemotherapy for newly diagnosed cardiac light-chain amyloidosis: a multicenter randomized controlled trial. Circulation. 2022;145(1):8–17.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, tours, France, 18-22 April 2004. Am J Hematol. 2005;79(4):319–328.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Merlini G. Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid. 2010;17:48–49.
   Web of Science ®Google Scholar
• Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325–2332.
   PubMed Web of Science ®Google Scholar